Sign in | Register
Services
Solutions
About Us
Resources
Contact Us
Accelerating Ideas Delivering Impact

Accelerating Ideas

Delivering Impact

Advancing discovery, biologics and cell & gene therapies through cutting edge science, intelligent technologies and lean manufacturing.

Explore Capabilities

ProBio Discovery Services – Antibody Discovery and Developability Assessment
Discovery
Our integrated discovery services deliver high‑quality, developable antibody candidates ready for CMC and IND‑enabling studies. 

Combining multiple lead‑generation platforms with expert antibody engineering, developability assessment, and in vitro/in vivo pharmacology, we help de‑risk programs early and accelerate the path to the clinic.

Demonstrated Track Record for ProBio

IND Clearances
Commercial Products or Medical Devices Supported
GMP Batches Successfully Delivered
CDMO Projects Ongoing

Accelerating Therapeutics with ProBio

Global Quality Compliance

Our Phase‑Appropriate Compliance (PAC) quality system meets global regulatory standards (FDA, EMA, NMPA), ensuring quality, efficiency, and credibility at every stage.

Global Quality Compliance – Regulatory Standards FDA, EMA, NMPA

Regulatory Affairs

ProBio supports regulatory success and seamless technology transfer through phase‑appropriate CMC strategies, global regulatory alignment, and experienced tech‑transfer execution, including dedicated support for Investigator‑Initiated Trials (IITs).

End-to-End Regulatory Support – CMC Strategy and Technology Transfer

Proven Expertise

ProBio has supported hundreds of biologics and cell & gene therapy programs across discovery, IND‑enabling, clinical, and early commercial stages. With our years of people and project expertise, we consistently move projects forward.

Proven CMC Expertise – Hundreds of Biologics and CGT Programs

Global Capacity

ProBio’s global footprint integrates discovery, CMC, and GMP manufacturing capabilities across biologics and CGT sites, enabling seamless tech transfer, regulatory alignment, and scalable delivery from early development through commercialization.

Integrated Global Capacity – Biologics and CGT Sites Worldwide

Solutions

In Vivo CAR-T

In Vivo CAR-T

We support in vivo CAR‑T development through integrated plasmid, lentiviral vector, and mRNA/RNA‑tLNP platforms, combined with targeted delivery design and IND‑ready CMC execution. Our end‑to‑end capabilities help simplify development, reduce risk, and accelerate in vivo CAR‑T programs to the clinic.
Bispecific and Trispecific Antibodies

Bispecific and Trispecific Antibodies

We support antibody programs with specialized discovery platforms, format‑specific CMC strategies, and GMP manufacturing expertise. By addressing developability, manufacturability, and regulatory needs early, we help de‑risk complex multi‑specific antibodies and accelerate their path to the clinic.
Antibody Drug Conjugates (ADCs)

Antibody Drug Conjugates (ADCs)

We support development through integrated antibody discovery and optimization, bispecific‑ready CMC strategies, and GMP biologics manufacturing. With deep expertise in complex antibodies, conjugation‑relevant analytics, and IND‑ready regulatory execution, we help ensure ADC candidates are stable, manufacturable, and ready to advance confidently to the clinic.
Targeted Delivery Technologies

Targeted Delivery Technologies

ProBio advances targeted delivery technologies through antibody‑directed RNA‑tLNP and targeted lentiviral vector (tLVV) platforms, enabling efficient and selective in vivo gene delivery. These integrated, IND‑ready solutions help accelerate next‑generation in vivo CAR‑T and other advanced therapies to the clinic.

ProBio's U.S. GMP Manufacturing Hub in New Jersey

ProBio's U.S. headquarters and GMP biologics manufacturing facility in New Jersey will be fully operational in May 2026. The site provides U.S.-based biotech and pharma partners with access to ProBio's high-performing CHO-K1 platform, onshore drug substance manufacturing, analytical testing, and regulatory support. Integrated with ProBio's global network, the facility enables seamless scale-up and tech transfer-free progression from development to commercial manufacturing, supported by local supply chain reliability and direct access to ProBio's senior CMC experts.
00:00
00:00

Latest News

Stay updated with our latest news.

ProBio Proudly Supports the Emily Whitehead Foundation Believe Ball
News

ProBio Proudly Supports the Emily Whitehead Foundation Believe Ball

ProBio, a subsidiary of GenScript, is proud to support the Emily Whitehead Foundation Believe Ball as a Diamond Sponsor, standing alongside patients, families, clinicians, and researchers working to transform the future of cancer and rare disease treatment.
ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China
News

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness
News

ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness

ProBio CDMO Expands Viral Vector Development Capabilities at US site with New Packaging Test Platform
News

ProBio CDMO Expands Viral Vector Development Capabilities at US site with New Packaging Test Platform

ProBio CDMO – Bringing Life-Saving Therapies to Patients Faster

Bringing Life-Saving Therapies to Patients,

Faster

We can help you move your projects forward. Let us know your project stage and contact information.

Our technical consultants will prepare a personalized solution for you.

Contact ProBio's Team
US

ProBio's GMP Facility in New Jersey

China

ProBio's Flagship in Nanjing

Europe

ProBio's Client Liaison in EMEA

APAC

ProBio in Korea, Japan & Singapore